Mineralys Therapeutics
Develops targeted medicines for aldosterone-driven cardiorenal diseases.
Company facts
- Founded
- 2019
- Employees
- 51
- Headquarters
- United States
- CEO
- Jon Congleton
- Type
- Public
- Listed
- NASDAQ: MLYS
About
Mineralys Therapeutics is dedicated to providing innovative solutions for the management of hypertension. The company is driven by the need to address the growing challenges associated with elevated blood pressure and the prevalence of cardiovascular diseases worldwide. One key area of focus for Mineralys is aldosterone, a hormone that plays a critical role in regulating blood pressure and fluid balance. Through targeted research and development efforts, Mineralys aims to bring forward new therapies that can effectively help patients control their hypertension and improve their overall heart health. The company believes that understanding the importance of aldosterone is essential for developing therapeutic approaches that can significantly impact the management of hypertension and associated conditions. As they continue to evolve in the complex field of therapeutics, Mineralys remains committed to enhancing patient outcomes and fostering innovation in cardiovascular medicine.